IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.02% USD/MXN18.63▲ 0.01% USD/CLP 975.74 — 0.00% USD/COP3,238▼ 0.08% USD/PEN3.43▼ 0.35% USD/ARS1,545▼ 0.03% USD/UYU 40.31 — 0.00% USD/PYG 6,358 — 0.00% USD/BOB 11.81 — 0.00% USD/DOP60.63▲ 0.07% USD/CRC448.27— 0.00% USD/GTQ 7.64 — 0.00% USD/HNL26.88▲ 3.19% USD/NIO 36.62 — 0.00% USD/VES895.29▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.83— 0.00% USD/TTD6.72▲ 2.44% EUR/BRL6.15▲ 0.40% BRENT 96.73 ▼ 1.62% WTI 89.86 ▼ 1.07% IRON ORE 161.91 — — COPPER 6.31 ▲ 1.53% GOLD 4,109 ▲ 0.83% SILVER 52.30 ▲ 0.96% SOY 1,195 ▲ 0.46% CORN 441.25 ▼ 0.06% WHEAT 588.00 ▼ 0.55% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00% IBOV 168,498.45 ▲ 1.39% IPC MEX 71,393.57 ▲ 0.43% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.02% USD/MXN 18.61 ▼ 0.10% USD/CLP 975.74 — 0.00% USD/COP 3,238 ▼ 0.08% USD/PEN 3.44 ▲ 0.02% USD/ARS 1,545 ▼ 0.03% USD/UYU 40.31 — 0.00% USD/PYG 6,358 — 0.00% USD/BOB 11.81 — 0.00% USD/DOP 60.63 ▲ 0.07% USD/CRC 448.27 ▲ 2.01% USD/GTQ 7.64 — 0.00% USD/HNL 26.88 ▲ 3.19% USD/NIO 36.62 — 0.00% USD/VES 895.29 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.99 ▲ 2.78% USD/TTD 6.72 ▲ 2.44% EUR/BRL 6.15 ▲ 0.37% BRENT 96.73 ▼ 1.62% WTI 89.86 ▼ 1.07% IRON ORE 161.91 — — COPPER 6.31 ▲ 1.53% GOLD 4,109 ▲ 0.83% SILVER 52.30 ▲ 0.96% SOY 1,195 ▲ 0.46% CORN 441.25 ▼ 0.06% WHEAT 588.00 ▼ 0.55% COFFEE 280.15 ▲ 1.08% SUGAR 18.25 ▼ 1.67% ORANGE JUICE 130.55 ▲ 1.63% COTTON 78.54 ▼ 0.22% COCOA 5,119 ▼ 1.20% BEEF 214.05 ▼ 0.16% CATTLE 318.38 ▼ 2.05% LITHIUM 60.91 ▲ 1.21% PETR4 45.36 — 0.00% VALE3 64.04 — 0.00% ITUB4 40.53 — 0.00% BBDC4 14.20 — 0.00% ABEV3 15.48 — 0.00% BBAS3 17.13 — 0.00% B3SA3 14.39 — 0.00% WEGE3 48.19 — 0.00% PRIO3 60.48 — 0.00% SUZB3 53.40 ▲ 2.12% RENT3 30.29 — 0.00% AZZA3 14.76 ▲ 4.98% CSAN3 2.77 — 0.00% RAIZ4 28.00 ▲ 2.56% PCAR3 2.40 ▲ 0.42% GMAT3 3.80 — 0.00% PSSA3 44.35 ▲ 1.46% CVCB3 0.84 ▲ 2.44% POSI3 3.09 ▼ 0.64% SLCE3 16.61 ▲ 1.59% NATU3 5.17 — 0.00% BRKM5 3.20 — 0.00% RANI3 8.53 ▲ 0.83% CSNA3 4.41 — 0.00%
since 2009
Monday, November 9, 2026

Latest News Brazil

Canadian Researchers Say Marijuana Active Ingredients Can Block Coronavirus Infection

By · · 2 min read

RIO DE JANEIRO, BRAZIL – Studies by scientists at the University of Lethbridge, Canada, show that the medicinal strain of Cannabis sativa can serve as an important inhibitor to the spread of the coronavirus in the body.

Igor Kovalchuk believes that the main factor ensuring the effectiveness of such a treatment is the correct balance of THC and cannabidiol (CBD).
Igor Kovalchuk believes that the main factor ensuring the effectiveness of such a treatment is the correct balance of THC and cannabidiol (CBD).
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

According to researcher Igor Kovalchuk, at least 12 of the plant’s 400 varieties that have been tested in laboratories have succeeded in reducing the number of receptors of the virus by 73 percent.

“If they can reduce the number of receptors, there is much less chance of infection,” Kovalchuk told journalist Bill Kaufmann of the Canadian newspaper Calgary Herald.

The study conducted by the group linked to the researcher was published on Preprints.org and has yet to be reviewed by other scientists, but according to Kovalchuk it could help encourage research with cannabis.

According to him, few substances are capable of reducing between 70 and 80 percent of coronavirus receptors. He believes that the main factor ensuring the effectiveness of such a treatment is the correct balance of tetrahydrocannabinol (THC) and cannabidiol (CBD).

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Paraguay's Senate ousts its president after a bank failure”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

Israeli biotechnology company Stero Biotechs began testing the administration of CBD to patients with Covid-19 at the Rabin Medical Center. Ten patients will undergo cannabidiol steroid therapy.

In late April, Brazil’s health regulatory agency ANVISA released the sale of the first cannabis-based product in Brazil, a herbal medicine with a THC concentration of up to 0.2 percent.

In 2019, an ANVISA resolution approved the establishment of a new category of cannabis-based products; it went into effect on March 10th this year. From that date on, companies interested in manufacturing and marketing these products were entitled to apply for authorization from the agency.

Source: Fórum

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.